34
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: not found

      Hyperlipoproteinemia in renal insufficiency.

      Nephron. Physiology
      Animals, Cholesterol, blood, Fatty Acids, Nonesterified, Humans, Hyperinsulinism, complications, Hyperlipoproteinemias, etiology, therapy, Kidney Diseases, Kidney Failure, Chronic, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Renal Dialysis, Triglycerides, Uremia, metabolism

      Read this article at

      ScienceOpenPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In uremic patients, hyperlipoproteinemia is common, but its role as a risk factor in atherogenesis remains controversial. The main abnormality appears to be diminished catabolism of lipoproteins in the face of unchanged or low hepatic synthesis. The relation of diminished catabolism to reduced postheparinlipolytic activity and selective deficiency of hepatic triglyceride lipase remains to be established. Hyperlipoproteinemia in uremic patients, most commonly of the type IV variety, responds to dietary methods (reduction of carbohydrate content, increase in P/S ratio) or pharmacological intervention. Guidelines for therapy remain controversial in view of the uncertainty about the pathogenic role of hyperlipoproteinemia in atherogenesis.

          Related collections

          Author and article information

          Comments

          Comment on this article